Compare Divis Laboratories with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TTK HEALTHCARE - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TTK HEALTHCARE DIVIS LABORATORIES/
TTK HEALTHCARE
 
P/E (TTM) x 34.6 17.3 200.0% View Chart
P/BV x 6.6 1.4 479.3% View Chart
Dividend Yield % 0.9 1.1 82.5%  

Financials

 DIVIS LABORATORIES   TTK HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
TTK HEALTHCARE
Mar-19
DIVIS LABORATORIES/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,6391,215 134.9%   
Low Rs1,115610 182.8%   
Sales per share (Unadj.) Rs186.3444.4 41.9%  
Earnings per share (Unadj.) Rs51.017.2 295.5%  
Cash flow per share (Unadj.) Rs57.327.6 207.5%  
Dividends per share (Unadj.) Rs16.005.00 320.0%  
Dividend yield (eoy) %1.20.5 212.0%  
Book value per share (Unadj.) Rs261.8177.9 147.1%  
Shares outstanding (eoy) m265.4714.13 1,878.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.1 359.9%   
Avg P/E ratio x27.052.9 51.1%  
P/CF ratio (eoy) x24.033.0 72.7%  
Price / Book Value ratio x5.35.1 102.6%  
Dividend payout %31.429.0 108.3%   
Avg Mkt Cap Rs m365,59212,894 2,835.3%   
No. of employees `00011.82.3 512.4%   
Total wages/salary Rs m5,4231,307 414.9%   
Avg. sales/employee Rs Th4,175.12,715.7 153.7%   
Avg. wages/employee Rs Th457.7565.3 81.0%   
Avg. net profit/employee Rs Th1,141.8105.4 1,083.3%   
INCOME DATA
Net Sales Rs m49,4636,279 787.8%  
Other income Rs m1,55678 2,008.1%   
Total revenues Rs m51,0196,356 802.7%   
Gross profit Rs m18,718496 3,776.9%  
Depreciation Rs m1,689147 1,151.3%   
Interest Rs m3534 103.6%   
Profit before tax Rs m18,551393 4,725.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023149 3,373.6%   
Profit after tax Rs m13,527244 5,550.8%  
Gross profit margin %37.87.9 479.4%  
Effective tax rate %27.137.9 71.4%   
Net profit margin %27.33.9 704.6%  
BALANCE SHEET DATA
Current assets Rs m46,5012,717 1,711.3%   
Current liabilities Rs m8,4681,571 539.1%   
Net working cap to sales %76.918.3 421.1%  
Current ratio x5.51.7 317.5%  
Inventory Days Days13132 406.8%  
Debtors Days Days8647 184.0%  
Net fixed assets Rs m25,797991 2,603.1%   
Share capital Rs m531141 375.7%   
"Free" reserves Rs m68,9622,373 2,906.1%   
Net worth Rs m69,4932,514 2,763.9%   
Long term debt Rs m03 0.0%   
Total assets Rs m80,3834,158 1,933.2%  
Interest coverage x531.012.6 4,209.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.61.5 40.8%   
Return on assets %16.96.7 252.8%  
Return on equity %19.59.7 200.8%  
Return on capital %26.716.9 157.9%  
Exports to sales %03.6 0.0%   
Imports to sales %24.60.5 4,998.4%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs m12,18731 39,375.8%   
Fx inflow Rs m41,238225 18,311.5%   
Fx outflow Rs m12,40571 17,444.9%   
Net fx Rs m28,833154 18,711.5%   
CASH FLOW
From Operations Rs m9,543173 5,513.0%  
From Investments Rs m-6,85497 -7,102.6%  
From Financial Activity Rs m-2,459-307 800.3%  
Net Cashflow Rs m230-38 -609.0%  

Share Holding

Indian Promoters % 52.0 65.4 79.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 5.2 365.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 25.8 66.7%  
Shareholders   31,796 12,723 249.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS